Scolaris Content Display Scolaris Content Display

Study flow diagram.
Figuras y tablas -
Figure 1

Study flow diagram.

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
Figuras y tablas -
Figure 2

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Risk of bias summary: review authors' judgements about each risk of bias item for each included trial.
Figuras y tablas -
Figure 3

Risk of bias summary: review authors' judgements about each risk of bias item for each included trial.

Forest plot of comparison: 1 Prevention of post‐bronchiolitis syndrome (antibiotics vs placebo), outcome: 1.1 Number of participants who were not cured at follow‐up (up to 6 months).
Figuras y tablas -
Figure 4

Forest plot of comparison: 1 Prevention of post‐bronchiolitis syndrome (antibiotics vs placebo), outcome: 1.1 Number of participants who were not cured at follow‐up (up to 6 months).

Forest plot of comparison: 1 Prevention of post‐bronchiolitis syndrome (antibiotics vs placebo), outcome: 1.2 Number of participants who were rehospitalised within 6 months.
Figuras y tablas -
Figure 5

Forest plot of comparison: 1 Prevention of post‐bronchiolitis syndrome (antibiotics vs placebo), outcome: 1.2 Number of participants who were rehospitalised within 6 months.

Forest plot of comparison: 1 Prevention of post‐bronchiolitis syndrome (antibiotics vs placebo), outcome: 1.3 Proportion of participants with wheeze (within 6 months of intervention).
Figuras y tablas -
Figure 6

Forest plot of comparison: 1 Prevention of post‐bronchiolitis syndrome (antibiotics vs placebo), outcome: 1.3 Proportion of participants with wheeze (within 6 months of intervention).

Comparison 1 Prevention of post‐bronchiolitis syndrome (antibiotics vs placebo), Outcome 1 Number of participants who were not cured at follow‐up (up to 6 months).
Figuras y tablas -
Analysis 1.1

Comparison 1 Prevention of post‐bronchiolitis syndrome (antibiotics vs placebo), Outcome 1 Number of participants who were not cured at follow‐up (up to 6 months).

Comparison 1 Prevention of post‐bronchiolitis syndrome (antibiotics vs placebo), Outcome 2 Number of participants who were rehospitalised within 6 months.
Figuras y tablas -
Analysis 1.2

Comparison 1 Prevention of post‐bronchiolitis syndrome (antibiotics vs placebo), Outcome 2 Number of participants who were rehospitalised within 6 months.

Comparison 1 Prevention of post‐bronchiolitis syndrome (antibiotics vs placebo), Outcome 3 Proportion of participants with wheeze (within 6 months of intervention).
Figuras y tablas -
Analysis 1.3

Comparison 1 Prevention of post‐bronchiolitis syndrome (antibiotics vs placebo), Outcome 3 Proportion of participants with wheeze (within 6 months of intervention).

Summary of findings for the main comparison. Antibiotics compared with placebo or no treatment for persistent respiratory symptoms following acute bronchiolitis

Antibiotics compared with placebo or no treatment for persistent respiratory symptoms following acute bronchiolitis

Patient or population: children < 24 months with persistent respiratory symptoms following acute bronchiolitis
Setting: post‐acute bronchiolitis phase > 14 days
Intervention: antibiotics^
Comparison: placebo or no treatment^

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

No. of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Risk with placebo

Risk with antibiotics

Number of participants who were not cured at follow‐up
Follow‐up: 6 months

234 per 1000

174 per 1000
(102 to 282)

OR 0.69
(0.37 to 1.28)

249
(2 RCTs)

⊕⊕⊝⊝
LOWa

Number of participants rehospitalised for a respiratory illness
Follow‐up: 6 months

238 per 1000

271 per 1000
(173 to 398)

OR 1.19
(0.67 to 2.12)

240
(2 RCTs)

⊕⊕⊝⊝
LOWa

Proportion of participants with recurrent wheeze
Follow‐up: 6 months

123 per 1000

99 per 1000
(47 to 195)

OR 0.47

(0.06 to 3.95)

240
(2 RCTs)

⊕⊕⊝⊝
LOWa

^Intervention/Comparison group: treatment initiated during child's hospitalisation for acute bronchiolitis

*The risk in the intervention group (and its 95% confidence interval) is based on assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI)
CI: confidence interval; OR: odds ratio

We used GRADEPro software to create this table (GRADEpro GDT 2015)

GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

aQuality downgraded because of small numbers of studies and participants and high attrition in the Tahan study. Hence, we cannot be confident of the effect estimate

Figuras y tablas -
Summary of findings for the main comparison. Antibiotics compared with placebo or no treatment for persistent respiratory symptoms following acute bronchiolitis
Comparison 1. Prevention of post‐bronchiolitis syndrome (antibiotics vs placebo)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Number of participants who were not cured at follow‐up (up to 6 months) Show forest plot

2

249

Odds Ratio (M‐H, Fixed, 95% CI)

0.69 [0.37, 1.28]

2 Number of participants who were rehospitalised within 6 months Show forest plot

2

240

Odds Ratio (M‐H, Random, 95% CI)

0.54 [0.05, 6.21]

3 Proportion of participants with wheeze (within 6 months of intervention) Show forest plot

2

240

Odds Ratio (M‐H, Random, 95% CI)

0.47 [0.06, 3.95]

Figuras y tablas -
Comparison 1. Prevention of post‐bronchiolitis syndrome (antibiotics vs placebo)